From GlobeNewswire:

Biopharmaceutical company Korro Bio, Inc. presented positive data for KRRO-110 at the J.P. Morgan Healthcare Conference, citing potentially best-in-class results in treating AATD, a genetic disorder. Preclinical research showed KRRO-110 could generate a protein variant and achieve greater than 50% editing in non-human primates. The company also shared progress on its RNA editing platform and pipeline. Regulatory filing for KRRO-110 is expected in late 2024, with potential interim clinical readout in 2025. Platform OPERA™ integrates adenosine deaminase acting on RNA (ADAR) enzymology with oligonucleotide chemistry and machine learning optimization for RNA editing, achieving greater than 50% editing in vivo in preclinical studies. Korro used CHORDs to demonstrate selective modulation of TDP-43 to reduce protein aggregation and modulate ion channels to within physiological levels in Nav1.7. RNA editing changes amino acids on proteins to endow them with desired altered properties while preserving their broader functional capabilities. In addition to treating AATD, Korro’s platform has the potential to be used for a range of rare and highly prevalent diseases. For more information, visit korrobio.com.



Read more: Korro Bio Highlights Data for its Lead Program in Alpha-1